Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has provided an announcement.
Thiogenesis Therapeutics reported interim Phase 2 EU data for its lead drug TTI-0102 in patients with MELAS, showing that optimized once-daily, weight-based dosing around 60 mg/kg/day produced statistically significant improvements in patient-reported fatigue and favorable pharmacokinetic and pharmacodynamic profiles. The results, highlighted at the Mitocon 2026 mitochondrial medicine conference, suggest improved tolerability versus fixed dosing and existing cysteamine formulations, support the proposed mechanism of action in mitochondrial energy metabolism and oxidative stress reduction, and provide a clear dosing and biomarker roadmap for future trials, including the company’s planned Phase 2a program in Leigh syndrome spectrum.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp. is a clinical-stage biotechnology company focused on developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases. Its lead candidate, TTI-0102, targets conditions such as MELAS and Leigh syndrome spectrum, positioning the company within the niche but high-need market for mitochondrial medicine.
Average Trading Volume: 24,890
Technical Sentiment Signal: Sell
Current Market Cap: C$31.1M
Learn more about TTI stock on TipRanks’ Stock Analysis page.